(Q33358304)

26 July 2017

title

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase (English)

1 reference

26 July 2017

1 reference

1 reference

2

Hagop M Kantarjian

1 reference

26 July 2017

10

Stefan Faderl

1 reference

26 July 2017

9

William Wierda

1 reference

26 July 2017

4

Susan O'Brien

1 reference

26 July 2017

5

Mary Beth Rios

1 reference

26 July 2017

11

Francis Giles

1 reference

26 July 2017

12

Jorge E Cortes

1 reference

26 July 2017

3

Moshe Talpaz

1 reference

26 July 2017

8

Debra Resta

1 reference

26 July 2017

Thomas B Sneed

1

1 reference

26 July 2017

B Nebiyou Bekele

series ordinal

6

1 reference

26 July 2017

Xian Zhou

series ordinal

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

100

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

116-121

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Practical management of patients with chronic myeloid leukemia receiving imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11863

7 January 2021

Identifiers

DOI

10.1002/CNCR.11863

1 reference

26 July 2017

1 reference